Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 3
1970 2
1971 1
1974 1
1977 1
1981 2
1982 1
1983 1
1984 3
1985 5
1986 10
1987 11
1988 9
1989 8
1990 10
1991 11
1992 11
1993 9
1994 7
1995 9
1996 13
1997 10
1998 11
1999 10
2000 11
2001 11
2002 10
2003 11
2004 10
2005 9
2006 8
2007 5
2008 7
2009 7
2010 16
2011 10
2012 8
2013 13
2014 15
2015 21
2016 15
2017 15
2018 15
2019 16
2020 26
2021 24
2022 32
2023 29
2024 43
2025 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

546 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of Nebulized Ketamine to Intravenous Subdissociative Dose Ketamine for Treating Acute Painful Conditions in the Emergency Department: A Prospective, Randomized, Double-Blind, Double-Dummy Controlled Trial.
Nguyen T, Mai M, Choudhary A, Gitelman S, Drapkin J, Likourezos A, Kabariti S, Hossain R, Kun K, Gohel A, Niceforo P, Silver M, Motov S. Nguyen T, et al. Among authors: mai m. Ann Emerg Med. 2024 Oct;84(4):354-362. doi: 10.1016/j.annemergmed.2024.03.024. Epub 2024 May 2. Ann Emerg Med. 2024. PMID: 38703175 Clinical Trial.
Effector memory-type regulatory T cells display phenotypic and functional instability.
Wendering DJ, Amini L, Schlickeiser S, Farrera-Sal M, Schulenberg S, Peter L, Mai M, Vollmer T, Du W, Stein M, Hamm F, Malard A, Castro C, Yang M, Ranka R, Rückert T, Durek P, Heinrich F, Gasparoni G, Salhab A, Walter J, Wagner DL, Mashreghi MF, Landwehr-Kenzel S, Polansky JK, Reinke P, Volk HD, Schmueck-Henneresse M. Wendering DJ, et al. Among authors: mai m. Sci Adv. 2024 Sep 6;10(36):eadn3470. doi: 10.1126/sciadv.adn3470. Epub 2024 Sep 4. Sci Adv. 2024. PMID: 39231218 Free PMC article.
Induction of immune tolerance in living related human leukocyte antigen-matched kidney transplantation: A phase 3 randomized clinical trial.
Kaufman DB, Akkina SK, Stegall MD, Piper JB, Gaber AO, Asch WS, Busque S, Stites E, De Vera M, Srinivas TR, Alonso D, Shah A, Patel A, Mai ML, Chavin KD, DebRoy M, Jittirat A, Costa N, Cooper M, Vranic G, Laftavi MR, Saidi RF, Collette S, Brennan DC; MDR-101-MLK Study Group. Kaufman DB, et al. Among authors: mai ml. Am J Transplant. 2025 Jul;25(7):1461-1470. doi: 10.1016/j.ajt.2025.01.044. Epub 2025 Feb 6. Am J Transplant. 2025. PMID: 39922283 Clinical Trial.
Primary Jejunal Angiosarcoma.
Mai M, Gupta S, Farrakhan K, Lu S, Akerman P, Min M. Mai M, et al. ACG Case Rep J. 2025 Aug 27;12(8):e01818. doi: 10.14309/crj.0000000000001818. eCollection 2025 Aug. ACG Case Rep J. 2025. PMID: 40881117 Free PMC article.
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, Hughes A, Mai M, King M, Solanki A, Magiera L, Miragaia R, Kar G, Standifer N, Surace M, Gill S, Peter A, Talbot S, Tohumeken S, Fryer H, Mostafa A, Mulgrew K, Lam C, Hoffmann S, Sutton D, Carnevalli L, Calero-Nieto FJ, Jones GN, Pierce AJ, Wilson Z, Campbell D, Nyoni L, Martins CP, Baker T, Serrano de Almeida G, Ramlaoui Z, Bidar A, Phillips B, Boland J, Iyer S, Barrett JC, Loembé AB, Fuchs SY, Duvvuri U, Lou PJ, Nance MA, Gomez Roca CA, Cadogan E, Critichlow SE, Fawell S, Cobbold M, Dean E, Valge-Archer V, Lau A, Gabrilovich DI, Barry ST. Hardaker EL, et al. Among authors: mai m. Nat Commun. 2024 Feb 24;15(1):1700. doi: 10.1038/s41467-024-45996-4. Nat Commun. 2024. PMID: 38402224 Free PMC article.
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.
Teisseyre M, Allinovi M, Audard V, Cremoni M, Belvederi G, Karamé A, Accinno M, Duquesne J, Sharma V, Fernandez C, Zorzi K, El Maï M, Brglez V, Benzaken S, Esnault VLM, Vultaggio A, Kohli HS, Ramachandran R, Cirami CL, Seitz-Polski B. Teisseyre M, et al. Among authors: el mai m. Kidney Int Rep. 2024 Dec 17;10(3):753-761. doi: 10.1016/j.ekir.2024.12.012. eCollection 2025 Mar. Kidney Int Rep. 2024. PMID: 40225374 Free PMC article.
546 results